Pediatrics · LP-008
Paracetamol Suppositories
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-008Pediatrics
- Generic identity
- ParacetamolSuppository
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-008
- Generic identity
- Paracetamol
- Presentation
- Suppository
- Catalogue strength
- 125 mg; 250 mg
- Catalogue pack
- Strip or blister; carton 10 units
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: paracetamol.
- Dosage form/route presentation: suppository.
- Proposed strengths: 125 mg and 250 mg.
- General proposed pack: strip or blister; carton 10 units.
Layer 02 · Unresolved product-specific fields
- Suppository base/excipients, unit dimensions and whether units may be divided.
- Strength-to-container mapping between strip/blister presentations.
- Approved age/weight range, indication and administration instructions.
- Storage, shelf life, registration, manufacturing route and supply status.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 125 mg | Suppository | — | Strip or blister; carton 10 units; strength-container mapping not supplied | Rectal product-specific instructions and divisibility require the exact label/specification. |
| B | 250 mg | Suppository | — | Strip or blister; carton 10 units; strength-container mapping not supplied | Rectal product-specific instructions and divisibility require the exact label/specification. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Paracetamol, also called acetaminophen, is an analgesic and antipyretic used for pain and fever in appropriate patients. It is distinct from anti-inflammatory medicines such as ibuprofen. Different oral and rectal presentations contain the same active ingredient, so exposure from all products must be considered together. This educational profile describes the medicine generally; the approved indication, age range and instructions for a Luang Pharma presentation require its own authorized labeling.
Clinical context and therapeutic role
The clinical task is to relieve discomfort while recognizing the cause of persistent or severe symptoms. Fever with breathing difficulty, marked lethargy, dehydration, or other concerning features needs medical assessment rather than repeated symptom suppression. Children require an age-appropriate presentation and a professional or label-based plan. Combination cold, flu and pain products may also contain paracetamol, which is why a complete medication history is particularly important.
Selected safety context
Excess paracetamol can cause severe liver injury, sometimes before a person feels unwell. Suspected overdose requires urgent medical or poison-service advice even if there are no symptoms. Liver disease, heavy alcohol use, malnutrition and other medicines can affect safety. Avoid unintentionally combining several paracetamol-containing products. Serious allergy and severe skin reactions are possible. Persistent pain or fever should be reassessed; changing between oral and rectal forms does not avoid the overdose risk.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue identifies a rectal suppository. It is a different administration route from an oral tablet and should be clearly distinguished in labeling and selection. The base, physical characteristics and permission to divide a suppository require product-specific evidence rather than assumption from ingredient strength.
Keep each unit in its protective packaging until needed, and follow the exact instructions for storage and rectal administration. Do not swallow a suppository or substitute it for an oral medicine without professional advice. Product-specific limits on division and handling must be checked.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A pediatric clinician or pharmacist should confirm the diagnosis, authorized age range, weight-related assessment where relevant, concentration and measuring device. Catalogue placement in a pediatric category is not evidence of approval for children.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification for each strength and suppository base.
Approved rectal-product label/leaflet with age/weight and administration instructions.
Strength-to-pack/SKU matrix.
Registration/market-status evidence for each exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07a checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Acetaminophen rectalArchived source classification: US National Library of Medicine route-specific medicine reference | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval or evidence of equivalence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-008.
Professional enquiries
Request product-specific evidence for LP-008.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.